HK52787A - Stabilised ophthalmic formulation - Google Patents
Stabilised ophthalmic formulationInfo
- Publication number
- HK52787A HK52787A HK527/87A HK52787A HK52787A HK 52787 A HK52787 A HK 52787A HK 527/87 A HK527/87 A HK 527/87A HK 52787 A HK52787 A HK 52787A HK 52787 A HK52787 A HK 52787A
- Authority
- HK
- Hong Kong
- Prior art keywords
- formulation
- isotonic
- formulations
- trimethoprim
- polymyxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (8)
1. Formulation pharmaceutique liquide isotonique comprenant du trimethoprim et de la polymyxine, un véhicule pour ceux-ci, un agent de conservation contenant du mercure et un agent isotonique, caractérisée en ce que l'agent isotonique comprend un composé polyhydroxylé non ionique.
2. Formulation suivant la revendication 1, qui est une solution ophtalmique.
3. Formulation suivant la revendication 1 ou 2, dans laquelle l'agent isotonique est choisi parmi le dextrose, le lactose, le mannitol, le saccharose, le propylèneglycol, le glycérol et les polyéthylène- glycols d'un poids moléculaire inférieur à environ 750.
4. Formulation suivant l'une quelconque des revendications 1 à 3, dans laquelle la pression osmotique de la formulation est de 270 à 320 mosm/kg HzO.
5. Formulation suivant l'une quelconque des revendications 1 à 4, dans laquelle la pression osmotique de la formulation est de 280 à 300 mosm/kg H20.
6. Formulation suivant l'une quelconque des revendications 1 à 5, dans laquelle l'agent de conservation contenant du mercure est l'éthylmercurithiosalicylate de sodium.
7. Formulation ophtalmique isotonique aqueuse comprenant du triméthoprim (0,1 g), du sulfate de polymyxine B (1,1 méga-unité), de l'éthylmercurithiosalicylate de sodium (0,005 g) et du propylèneglycol (2,100 g) pour 100 ml de formulation.
8. Formulation ophtalmique liquide isotonique comprenant les constituants suivants pour 100 ml de produit final:
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8009589 | 1980-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK52787A true HK52787A (en) | 1987-07-17 |
Family
ID=10512277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK527/87A HK52787A (en) | 1980-03-21 | 1987-07-09 | Stabilised ophthalmic formulation |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP0037043B1 (fr) |
| JP (1) | JPS56150012A (fr) |
| KR (1) | KR830004856A (fr) |
| AU (1) | AU542560B2 (fr) |
| CA (1) | CA1168154A (fr) |
| CS (1) | CS261206B2 (fr) |
| CY (1) | CY1361A (fr) |
| DD (1) | DD157535A5 (fr) |
| DE (1) | DE3167270D1 (fr) |
| DK (1) | DK159414C (fr) |
| EG (1) | EG15051A (fr) |
| FI (1) | FI75991C (fr) |
| GB (1) | GB2072015B (fr) |
| GR (1) | GR73038B (fr) |
| HK (1) | HK52787A (fr) |
| HU (1) | HU185630B (fr) |
| IE (1) | IE51035B1 (fr) |
| IL (1) | IL62447A (fr) |
| IN (1) | IN153498B (fr) |
| IT (1) | IT8148073A0 (fr) |
| MC (1) | MC1379A1 (fr) |
| MY (1) | MY8700517A (fr) |
| NO (1) | NO155377C (fr) |
| NZ (1) | NZ196571A (fr) |
| PH (1) | PH17800A (fr) |
| PL (1) | PL138377B1 (fr) |
| PT (1) | PT72703B (fr) |
| SG (1) | SG20787G (fr) |
| ZA (1) | ZA811896B (fr) |
| ZW (1) | ZW6481A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62277323A (ja) * | 1986-02-19 | 1987-12-02 | Sankyo Co Ltd | フマル酸ケトチフエン含有点眼液の製法 |
| IL80298A (en) * | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| FR2622112A1 (fr) * | 1987-10-27 | 1989-04-28 | Medipro | Medicament comprenant l'association de polymyxine b, de neomycine et d'amphotericine b administre par vaporisation |
| ES2012532A6 (es) * | 1988-07-15 | 1990-04-01 | Cusi Lab | Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica. |
| WO1991012808A1 (fr) * | 1990-02-22 | 1991-09-05 | Macnaught Pty Limited | Larmes artificielles |
| DE4229494A1 (de) * | 1992-09-04 | 1994-03-10 | Basotherm Gmbh | Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks |
| ES2079994B1 (es) * | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
| TR201906789T4 (tr) | 2003-11-20 | 2019-05-21 | Novo Nordisk As | Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları. |
| NZ584275A (en) * | 2007-10-08 | 2012-06-29 | Fovea Pharmaceuticals | Aqueous cyclosporine ophthalmic formulations |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| PE20230819A1 (es) | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2703777A (en) * | 1950-05-02 | 1955-03-08 | Iso Sol Company Inc | Ophthalmological preparations and vehicles and method of making the same |
| GB1340517A (en) * | 1969-12-01 | 1973-12-12 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3898330A (en) * | 1973-08-01 | 1975-08-05 | Squibb & Sons Inc | Corticosteroid phosphate salts/neomycin sulfate ophthalmic |
| NL7416636A (nl) * | 1973-12-27 | 1975-07-01 | Wellcome Found | Farmaceutisch preparaat. |
-
1981
- 1981-03-20 DE DE8181102132T patent/DE3167270D1/de not_active Expired
- 1981-03-20 PH PH25391A patent/PH17800A/en unknown
- 1981-03-20 PL PL1981230236A patent/PL138377B1/pl unknown
- 1981-03-20 GB GB8108806A patent/GB2072015B/en not_active Expired
- 1981-03-20 KR KR1019810000921A patent/KR830004856A/ko not_active Ceased
- 1981-03-20 MC MC811508A patent/MC1379A1/fr unknown
- 1981-03-20 PT PT72703A patent/PT72703B/pt unknown
- 1981-03-20 NO NO810961A patent/NO155377C/no not_active IP Right Cessation
- 1981-03-20 DD DD81228491A patent/DD157535A5/de not_active IP Right Cessation
- 1981-03-20 CS CS812056A patent/CS261206B2/cs unknown
- 1981-03-20 CA CA000373477A patent/CA1168154A/fr not_active Expired
- 1981-03-20 ZW ZW64/81A patent/ZW6481A1/xx unknown
- 1981-03-20 CY CY136181A patent/CY1361A/xx unknown
- 1981-03-20 DK DK127181A patent/DK159414C/da not_active IP Right Cessation
- 1981-03-20 IT IT8148073A patent/IT8148073A0/it unknown
- 1981-03-20 ZA ZA00811896A patent/ZA811896B/xx unknown
- 1981-03-20 IE IE617/81A patent/IE51035B1/en not_active IP Right Cessation
- 1981-03-20 EP EP81102132A patent/EP0037043B1/fr not_active Expired
- 1981-03-20 HU HU81723A patent/HU185630B/hu unknown
- 1981-03-20 FI FI810870A patent/FI75991C/fi not_active IP Right Cessation
- 1981-03-20 AU AU68567/81A patent/AU542560B2/en not_active Expired
- 1981-03-20 GR GR64460A patent/GR73038B/el unknown
- 1981-03-20 NZ NZ196571A patent/NZ196571A/xx unknown
- 1981-03-20 JP JP4662981A patent/JPS56150012A/ja active Granted
- 1981-03-20 IL IL62447A patent/IL62447A/xx not_active IP Right Cessation
- 1981-03-21 EG EG155/81A patent/EG15051A/xx active
- 1981-03-21 IN IN306/CAL/81A patent/IN153498B/en unknown
-
1987
- 1987-02-26 SG SG207/87A patent/SG20787G/en unknown
- 1987-07-09 HK HK527/87A patent/HK52787A/en not_active IP Right Cessation
- 1987-12-30 MY MY517/87A patent/MY8700517A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4829083A (en) | Stabilization of mercury-containing preservatives in ophthalmic medicaments | |
| EP2068822B1 (fr) | Compositions pharmaceutiques aqueuses auto-conservées | |
| EP0473159B1 (fr) | Préparation aqueuse stable | |
| EP2066300B2 (fr) | Compositions pharmaceutiques aqueuses à conservation spontanée | |
| EP2420223B1 (fr) | Compositions pharmaceutiques aqueuses contenant des complexes de borate-polyol | |
| EP0037043B1 (fr) | Formulation ophtalmique stabilisée | |
| EP1666027A1 (fr) | Composition ophtalmique pour lentille de contact | |
| Lawrence | Antimicrobial activity, in vitro, of chlorhexidine | |
| KR101322527B1 (ko) | 잔탄 검 및 테르페노이드를 포함하는 점안제 | |
| US20100021561A1 (en) | Self-preserved aqueous pharmaceutical compositions | |
| EP2419081B1 (fr) | Compositions ophtalmiques aqueuses contenant des agents thérapeutiques anioniques | |
| Bailey et al. | The biological properties of chlorindanol, a new antiseptic agent | |
| HK1126419B (en) | Self-preserved aqueous pharmaceutical compositions | |
| HK1165327B (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| HK1155087A (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| HK1155087B (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| HK1145631B (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| HK1165327A (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE | Patent expired |